Pfizer (PFE) Other Non-Current Liabilities (2009 - 2026)

Pfizer (PFE) has 18 years of Other Non-Current Liabilities data on file, last reported at $3.7 billion in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 35.27% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (down 35.27% YoY) and the FY2025 annual result came in at $3.6 billion, down 41.25% from the prior year.
• Other Non-Current Liabilities improved to $3.7 billion in Q1 2026 per PFE's latest filing, from $3.6 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $16.1 billion in Q2 2024 and bottomed at $3.6 billion in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $8.6 billion (2024), against an average of $9.4 billion.
• Peak annual rise in Other Non-Current Liabilities reached 130.4% in 2025, while the deepest fall reached 41.25% in 2025.
• Tracing PFE's Other Non-Current Liabilities over 5 years: stood at $13.2 billion in 2022, then plunged by 35.25% to $8.5 billion in 2023, then dropped by 28.38% to $6.1 billion in 2024, then sank by 41.25% to $3.6 billion in 2025, then climbed by 3.17% to $3.7 billion in 2026.
• Per Business Quant, the three latest PFE Other Non-Current Liabilities figures stand at $3.7 billion (Q1 2026), $3.6 billion (Q4 2025), and $13.6 billion (Q3 2025).

Peer Comparison